HER2 Amplification: Mechanism, Targeted Therapy, and Resistance

HER2 Biology and Amplification Mechanism

HER2 is unique among the four ErbB family receptors in lacking a known high-affinity direct ligand, instead serving as the preferred heterodimerisation partner for EGFR, HER3, and HER4. The HER2 kinase domain is constitutively active and functions as the 'activator' kinase in asymmetric dimers, phosphorylating the partner ('receiver') receptor and creating docking sites for downstream signalling proteins. In HER2-amplified tumours, the massive increase in receptor density drives spontaneous receptor clustering and constitutive homodimerisation at densities sufficient for ligand-independent signalling.

HER2 amplification typically involves the 17q12-q21 chromosomal region and is defined clinically as HER2:CEP17 ratio ≥2.0 or average HER2 copy number ≥6.0 signals/cell by FISH. IHC score 3+ (uniform strong membrane staining in >10% of tumour cells) is considered HER2-positive without requiring FISH confirmation. HER2 amplification creates co-amplification of flanking genes — particularly GRB7 (a signalling adaptor), PERLD1, and TOP2A — which can independently contribute to the amplified-tumour phenotype.

Antibody-Drug Conjugates: T-DM1 and T-DXd

Trastuzumab emtansine (T-DM1) conjugates trastuzumab to the microtubule poison emtansine (DM1) via a non-cleavable linker, delivering high intracellular drug concentrations selectively to HER2+ tumour cells upon antibody internalisation. T-DM1 is approved for HER2+ breast cancer after progression on trastuzumab + taxane.

Trastuzumab deruxtecan (T-DXd, DS-8201) uses a cleavable tetrapeptide linker and a potent topoisomerase I inhibitor (DXd). The higher drug-antibody ratio (8:1 vs 3.5:1 for T-DM1) and membrane-permeable DXd payload create a 'bystander effect' — killing adjacent HER2-low or HER2-negative tumour cells through diffusion of released DXd. This bystander effect is the mechanistic basis for T-DXd activity in HER2-low (IHC 1+ or 2+/FISH−) breast cancer, demonstrated in the DESTINY-Breast04 trial and fundamentally expanding HER2-targeted therapy to this previously excluded population.

Resistance to HER2-Targeted Therapy

Primary resistance to trastuzumab occurs in approximately 50% of HER2+ metastatic breast cancers. The most common molecular mechanisms are PIK3CA activating mutations — present in ~30% of HER2+ tumours — which provide a parallel survival signal through AKT that bypasses HER2 inhibition; expression of truncated p95-HER2 lacking the trastuzumab-binding extracellular domain (generated by ADAM10/17-mediated shedding or alternative translation initiation); and HER3 overexpression, which recruits PI3K directly through its six YXXM motifs upon heterodimerisation with residual HER2 signalling.

Acquired resistance during trastuzumab therapy develops through overlapping mechanisms: PIK3CA mutation emergence under selective pressure, upregulation of compensatory receptor tyrosine kinases (MET, EGFR, IGF-1R), and PTEN loss driving constitutive AKT activity. Tucatinib — a highly selective HER2 kinase inhibitor — and neratinib — a pan-HER irreversible TKI — address resistance to extracellular-domain-targeting antibodies by more completely blocking intracellular HER2 kinase activity. The HER2CLIMB trial demonstrated that tucatinib plus trastuzumab plus capecitabine extended median PFS from 5.6 to 7.8 months (HR 0.54) and showed intracranial activity in brain metastases, a historically difficult-to-treat complication of HER2+ disease.

HER2 Across Tumour Types: Gastric, Lung, and Colorectal

HER2 overexpression or amplification occurs in ~15–20% of gastric and gastro-oesophageal junction (GEJ) adenocarcinomas. The ToGA trial demonstrated that adding trastuzumab to chemotherapy significantly improved median OS (13.8 vs 11.1 months; HR 0.74) in HER2-positive gastric and GEJ adenocarcinoma, establishing the first approved targeted therapy in this disease. T-DXd subsequently demonstrated 51% ORR in HER2-positive gastric cancer following prior trastuzumab (DESTINY-Gastric01), earning accelerated FDA approval and validating the pan-tumour principle that HER2 overexpression is actionable regardless of tissue origin.

In non-small cell lung cancer, HER2 activating mutations — predominantly exon 20 insertions (A775_G776insYVMA and similar) — occur in ~2–4% of lung adenocarcinomas and are mechanistically distinct from HER2 amplification, conferring constitutive kinase activation without receptor overexpression. T-DXd achieved 55% ORR in previously treated HER2-mutant NSCLC (DESTINY-Lung02), receiving FDA approval in 2022 and establishing exon 20 insertion testing as a standard component of NSCLC molecular profiling. In colorectal cancer (~5% HER2 amplification), tucatinib plus trastuzumab achieved 38% ORR in treatment-refractory patients (MOUNTAINEER trial), and T-DXd has demonstrated pan-tumour HER2-directed activity across biliary, endometrial, and other HER2-expressing solid tumours.

Key Takeaways

• ·HER2 amplification increases cell-surface receptor density 10–30-fold, enabling ligand-independent constitutive signalling through spontaneous homodimerisation and potent heterodimerisation with EGFR, HER3, and HER4.
• ·Trastuzumab binds HER2 domain IV, blocking shedding and downstream signalling while recruiting NK cells for antibody-dependent cellular cytotoxicity (ADCC); pertuzumab binds domain II to block HER2-HER3 heterodimerisation — their combination is synergistic and is standard first-line in HER2+ metastatic breast cancer.
• ·T-DXd's membrane-permeable DXd payload diffuses to adjacent tumour cells (bystander effect), extending activity to HER2-low breast cancer (IHC 1+ or 2+/FISH−) and pan-tumour HER2-expressing solid tumours beyond traditional HER2-amplified populations.
• ·PIK3CA mutations and p95-HER2 expression are the most common mechanisms of primary trastuzumab resistance, motivating combinations with PI3K/AKT inhibitors in HER2+/PIK3CA-mutant tumours.
• ·HER2-directed therapy is now approved across breast, gastric, lung (mutant), and colorectal cancers — one of the most broadly pan-tumour actionable targets in oncology.